Superpowers for Good

Superpowers for Good

SuperCrowd Voices

Combating Drug Resistance: A New Class of Anticancer Drugs Takes Aim at Cancer’s Evasive Tactics

A Multi-Targeted Family of Drugs That Kills Cancer Cells and Is Safe for Normal Cells

Dale's avatar
Dale
Apr 29, 2025
∙ Paid

We are pleased to share this SuperCrowd Voices from the Community post with you. SuperCrowd Voices posts represent the views of our guest authors, not The Super Crowd, Inc., a public benefit corporation. Manage the volume of emails you receive from us by clicking here. Interested in sharing your voice? Click here.

Dale M. Walker, DVM, specializes in pathology and drug development. She co-discovered the BRG drug family and has spent the last decade advancing these therapies for human and animal health.

Most Fatal Cancers Are Drug-Resistant

Across our lifespans, approximately 1 in 9 men and 1 in 12 women will die of cancer. In 2022, this resulted in over 600,000 deaths. Most of these deaths occur because tumors become resistant to treatment. Resistance is the reason why even the most promising treatments stop working; it’s why cancers come back. It is seen across essentially all aggressive cancer types. Drug resistance is one of the greatest obstacles to improving cancer treatment outcomes.

This post is for paid subscribers

Already a paid subscriber? Sign in
Dale's avatar
A guest post by
Dale
I am a veterinarian with post-doc training in pathology and decades of experience in research. I am the inventor on 2 patents that describe the activity of a new drug family that has broad applicability as anticancer agents and antiviral agents.
Subscribe to Dale
© 2026 Devin Thorpe · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.